We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Cards for Novavax (NVAX) This Earnings Season?
Read MoreHide Full Article
In the absence of an approved product, investors’ focus will be on the path forward for Novavax, Inc.’s (NVAX - Free Report) two vaccine candidates when the company reports first-quarter 2019 results.
The company’s earnings missed the Zacks Consensus Estimate in one of the last four quarters and matched the same thrice with the average negative surprise being 2.08%.
Shares of Novavax have declined 71.1% so far this year against the industry‘s rise of 4.7%.
In the last reported quarter, Novavax reported a positive earnings surprise of 8.33%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
Investors will likely focus on the path forward for the company’s lead vaccine candidates – ResVax and Nanoflu – on the first-quarter earnings call.
Novavax is planning to initiate a phase III study on its influenza vaccine candidate, Nanoflu, following the successful completion of a phase II study earlier in January. Data from the mid-stage study showed that Nanflu vaccine generated superior hemagglutination inhibition antibody (“HAI”) responses in patients compared to leading flu vaccine, Sanofi’s (SNY - Free Report) Fluzone.
In February, the company announced that pneumonia vaccine candidate, ResVax, failed to meet primary endpoint in a phase III study evaluating it in infant patients. However, Novavax expects to meet regulatory authorities to assess opportunities for submission of marketing application for ResVax based on efficacy against a secondary objective.
The development of ResVax was funded by a grant, which generated revenues for the company. However, with its failure to meet primary endpoint in the late-stage clinical study, the company is unlikely to generate any revenues in the soon-to-be reported quarter.
Research and development (R&D) expenses decreased in the last reported quarter due to lower development activities related to ResVax. We expect expenses to decrease in the first quarter following the completion of the ResVax late-stage study. However, increased developmental activity for Nanoflu is likely to offset the decline in R&D expenses.
Novavax is focused on developing vaccines for prevention of serious infectious diseases.
Earnings Whispers
Our proven model does not conclusively show that Novavax is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Novavax’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 12 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Novavax’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Horizon Pharma has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in the Cards for Novavax (NVAX) This Earnings Season?
In the absence of an approved product, investors’ focus will be on the path forward for Novavax, Inc.’s (NVAX - Free Report) two vaccine candidates when the company reports first-quarter 2019 results.
The company’s earnings missed the Zacks Consensus Estimate in one of the last four quarters and matched the same thrice with the average negative surprise being 2.08%.
Shares of Novavax have declined 71.1% so far this year against the industry‘s rise of 4.7%.
In the last reported quarter, Novavax reported a positive earnings surprise of 8.33%.
Let’s see how things are shaping up for this announcement.
Things to Watch Out For
Investors will likely focus on the path forward for the company’s lead vaccine candidates – ResVax and Nanoflu – on the first-quarter earnings call.
Novavax is planning to initiate a phase III study on its influenza vaccine candidate, Nanoflu, following the successful completion of a phase II study earlier in January. Data from the mid-stage study showed that Nanflu vaccine generated superior hemagglutination inhibition antibody (“HAI”) responses in patients compared to leading flu vaccine, Sanofi’s (SNY - Free Report) Fluzone.
In February, the company announced that pneumonia vaccine candidate, ResVax, failed to meet primary endpoint in a phase III study evaluating it in infant patients. However, Novavax expects to meet regulatory authorities to assess opportunities for submission of marketing application for ResVax based on efficacy against a secondary objective.
The development of ResVax was funded by a grant, which generated revenues for the company. However, with its failure to meet primary endpoint in the late-stage clinical study, the company is unlikely to generate any revenues in the soon-to-be reported quarter.
Research and development (R&D) expenses decreased in the last reported quarter due to lower development activities related to ResVax. We expect expenses to decrease in the first quarter following the completion of the ResVax late-stage study. However, increased developmental activity for Nanoflu is likely to offset the decline in R&D expenses.
Novavax is focused on developing vaccines for prevention of serious infectious diseases.
Earnings Whispers
Our proven model does not conclusively show that Novavax is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Novavax’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 12 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Although Novavax’s Zacks Rank #3 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction difficult.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Novavax, Inc. Price and Consensus
Novavax, Inc. Price and Consensus | Novavax, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Gilead Sciences, Inc. (GILD - Free Report) has an Earnings ESP of +1.54% and a Zacks Rank #2. The company is scheduled to release first-quarter results on May 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Horizon Pharma has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>